XORTX Therapeutics Inc. (NasdaqCM: XRTX)
Health Care · Pharmaceuticals · CA
$1.70
-11.46% today · -55.9% 1Y
XORTX Therapeutics Inc. (NasdaqCM: XRTX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.49M and employs 2 people.
Over the last twelve months the share price has lost 55.9%, trading between 1.59 and 7.05.
Tweenvest scores XORTX Therapeutics Inc. across four factors: quality 35/100, value 72/100. Its strongest factor is value.
XRTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.49M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.83
- Dividend yield
- —
- Beta (5Y)
- 0.44
- 52-week high
- $7.05
- 52-week low
- $1.59
- Avg volume (3M)
- —
- Shares outstanding
- 1.82M
- Employees
- 2
- Next earnings
- —
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
- ISIN
- CA98420Q4051
- Listed since
- Sep 23, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Blue Wave Water Capital LtdTASE: BLWV-M | $3.59M | ₪2.05 | +1.63% |
| PRF Technologies Ltd.NasdaqCM: PRFX | $3.57M | $1.00 | -1.96% |
| Cannabis Strategic VenturesOTCPK: NUGS | $3.54M | $0.01 | -11.11% |
| Goldline Pharmaceutical LimitedBSE: 544759 | $3.49M | Rs34.90 | -4.38% |
| RedHill Biopharma Ltd.NasdaqCM: RDHL | $3.46M | $0.54 | -4.43% |
| Rekvina Laboratories LimitedBSE: 526075 | $3.45M | Rs54.93 | -7.53% |
| 60 Degrees Pharmaceuticals, Inc.NasdaqCM: SXTP | $3.36M | $1.16 | +21.34% |
| PharmaTher Holdings Ltd.CNSX: PHRM | $3.27M | CA$0.05 | -9.09% |
Figures last refreshed Sep 20, 2026.